Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:INTS 30 October 2025 - 31 October 2025

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Biotech Bombshell: Intensity Therapeutics (INTS) Surges Nearly 400% on Major Cancer Trial News

Shares of Intensity Therapeutics closed at $1.32 on Oct. 30, surging nearly 395% intraday after Phase 1/2 trial data for INT230-6 showed a 75% disease-control rate in metastatic cancer. Over a billion shares traded, dwarfing the usual volume. After-hours, the price fell to around $0.90. The company’s market cap remains under $65 million.
31 October 2025
··
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Intensity Therapeutics shares surged nearly 200% on Oct. 30, 2025, after Phase 1/2 trial results for INT230-6 showed a 75% disease control rate and median survival of 11.9 months in advanced cancer patients. The stock traded around $0.27 with a market cap near $13.1 million and daily volume spiking to 279 million shares. INT230-6 is in late-stage trials for sarcoma and breast cancer.
30 October 2025
·
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 30.10.2025

US stocks fell Oct. 30, with the S&P 500 down 0.99% and Nasdaq off 1.57%. Oracle shares dropped 6.8% to $256.28 despite analysts raising price targets and maintaining buy ratings. Liberty Latin America slid about 6% in a month, closing near $7.77, well below its $10.63 fair value estimate. Intensity Therapeutics surged nearly 400%, while CERO plunged almost 95%.
30 October 2025
·······
Go toTop